Braintrain raises £485k in seed funding led by Mercia to expand operations and complete clinical trials.
The seed round was led by Mercia Fund Management with backing from angel investors.
Braintrain manufactures personalised health devices and wearable technology focused on sleep aid solutions. The firm produces patented systems that measure physiological metrics to deliver tailored cognitive behaviour therapy.
Braintrain has secured £485k in seed funding led by Mercia Fund Management, with participation from angel investors including senior sleep specialists and healthcare entrepreneurs. The capital will support business expansion and the completion of a formal clinical trial at a global top-tier sleep research centre.
The company develops SleepCogni, a patented device that measures vital signs such as heart rate, skin temperature and blood oxygen levels to provide personalised cognitive behaviour therapy via light and sound. The technology aims to address widespread sleep issues and reduce reliance on sleeping tablets.
Following successful pilot testing at Sheffield Hallam University, the firm intends to scale its operations within the global sleep aid market. Mercia backed the round to support the company through its upcoming growth phases.
From the founder
"Mercia is the perfect partner for us, as their 'Complete Capital Solution' will be able to meet our needs as a personalised healthcare technology start-up. We need an investor that understands our journey ahead and can help us plan for future growth."
Richard Mills
CEO at Braintrain
Investor perspective
"We have wanted to explore the consumer personalised healthcare market for a long time, and we are particularly excited about Braintrain 20:20, which has the potential to become industry-leading given the sector expertise of the team. The technology could also be modified for other health issues, thus allowing people to take control of their health, whilst decreasing the burden on stretched health services."
Ashish Patel
Mercia
Use of funds
- 01Expand into international markets
- 02Fund research and development
